OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
8
Results
Show all
Save search
Copy query
Show results for
Unknown
(8)
Publication Date
Release Date
2024
(3)
2022
(2)
2023
(1)
2021
(1)
2015
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Not available
S-EPMC7616360
|
biostudies-literature
Cite
Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
Not available
S-EPMC8734323
|
biostudies-literature
Cite
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Not available
S-EPMC7616389
|
biostudies-literature
Cite
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.
Not available
S-EPMC8725988
|
biostudies-literature
Cite
Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis.
Not available
S-EPMC9112652
|
biostudies-literature
Cite
Identification of six new susceptibility loci for invasive epithelial ovarian cancer.
Not available
S-EPMC4445140
|
biostudies-literature
Cite
Variability of oxygen requirements in critically ill COVID-19 patients.
Not available
S-EPMC10884784
|
biostudies-literature
Cite
Correction : Epidemiology and outcomes of early-onset AKI in COVID-19-related ARDS in comparison with non-COVID-19-related ARDS: insights from two prospective global cohort studies.
Not available
S-EPMC10214330
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets